Demystifying the potential of lipid-based nanocarriers in targeting brain malignancies.

Drug targeting for brain malignancies is restricted due to the presence of the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB), which act as barriers between the blood and brain parenchyma. Certainly, the limited therapeutic options for brain malignancies have made notable progress with enhanced biological understanding and innovative approaches, such as targeted therapies and immunotherapies. These advancements significantly contribute to improving patient prognoses and represent a promising shift in the landscape of brain malignancy treatments. A more comprehensive understanding of the histology and pathogenesis of brain malignancies is urgently needed. Continued research focused on unraveling the intricacies of brain malignancy biology holds the key to developing innovative and tailored therapies that can improve patient outcomes. Lipid nanocarriers are highly effective drug delivery systems that significantly improve their solubility, bioavailability, and stability while also minimizing unwanted side effects. Surface-modified lipid nanocarriers (liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, lipid nanocapsules, lipid-polymer hybrid nanocarriers, lipoproteins, and lipoplexes) are employed to improve BBB penetration and uptake through various mechanisms. This systematic review illuminates and covers various topics related to brain malignancies. It explores the different methods of drug delivery used in treating brain malignancies and delves into the benefits, limitations, and types of brain-targeted lipid-based nanocarriers. Additionally, this review discusses ongoing clinical trials and patents related to brain malignancy therapies and provides a glance into future perspectives for treating this condition.

Drug Release and Stability Study of Innovated Losartan Potassium and Rosuvastatin Calcium Fixed-dose Combination Tablet.

BACKGROUND: Patient adherence to therapy and compliance is always a challenge for care providers in the management of chronic disorders with multiple medications. OBJECTIVE: Our study focused on formulating concurrently prescribed ARB (Angiotensin Receptor Blocker), i.e., losartan potassium, and a cholesterol-lowering statin derivative, i.e., rosuvastatin calcium, in a fixed-dose combination tablet. METHODS: The drugs were selected based on the presence of synergism and variation in solubility characteristics. Trial batches with fixed concentrations of both active pharmaceutical ingredients (APIs) and varying quantities of different excipients were prepared by dry granulation technique and subjected to different quality control tests for tablets. Batch F5 was selected on the basis of in-process quality control data for the development of a drug release protocol. Experimental conditions were optimized. Based on the sink condition, phosphate buffer (pH 6.8) was selected as the dissolution medium. Simultaneous determination of both APIs in samples collected at predetermined time intervals was carried out using the RP-HPLC technique with acetonitrile, methanol, and water (20:25:55 v/v/v) as mobile phase. RESULTS: Complete dissolution of both APIs in the FDC tablet was achieved in 45 min in 900 mL of the selected medium. The in vitro drug release protocol was validated for accuracy and precision without interference with sample analysis. CONCLUSION: In this study, a validated, accurate, and robust dissolution testing method was developed for the newly formulated FDC tablet.

Nephrotoxic effects of Valeriana wallichii.

Aminoglycosides are the commonly used antibiotics against Gram negative bacteria. Their clinical applications are limited due to nephrotoxic side effects. Therefore, the current study was undertaken in an attempt to increase the use of these drugs without causing nephrotoxicity by exploring the nephroprotective effects of a medicinal plant with high flavonoid contents and strong antioxidant properties, namely Valeriana wallichii. A daily dose of 200mg/kg of the extract derived from V. wallichii was employed for a period of three weeks. The results obtained revealed that co-therapy of extract with gentamicin protected some changes in renal functions; however, failed to provide a complete protection as assessed by biochemical, physiological and histological parameters. It can be concluded from the current findings that V. wallichii failed to deliver protective effects against gentamicin induced renal damage in spite of strong flavonoid contents and antioxidant properties.

Nephroprotective property of Cinnamomum zeylanicum and its antibacterial activity in combination with gantamicin.

Cinnamomum zeylanicum has strong antioxidant properties and has been presented to have nephroprotective effects. Present work was aimed to study the nephroprotective property of the plant extract through urinary enzymes excretion, to confirm its protective effects and to observe the antibacterial activities of gentamicin in combination with the plant extract. 200mg/kg/day of the plant extracts were administered alone and as co-therapy with gentamicin. Urinary lactate dehydrogenase (LDH) and Urinary alkaline phospatase (ALP) excretions were observed through reagents kits with the help of Power-Lab 300. Antibacterial activities were assessed for gentamicin alone and in combination with the extract. Present study showed that the plant extract have excess quantity of flavonoids, which may responsible for attenuating the excessive excretion of urinary LDH. However, Urinary ALP excretion was found remained same throughout the study period in all experimental groups; might be detected in acute damage. Further, the plant also proved to have no decreasing impact on the antibacterial activities of gentamicin.

Nephro-protective potential of Morus alba, a prospective experimental study on animal models.

CONTEXT: Morus alba L. (Moraceae) is traditionally used for the treatment of urinary incontinency due its strong diuretic properties. OBJECTIVE: The present study explores the renal protective effects of M. alba, due to its free radical scavenging properties, in order to provide experimental evidence for its established use. MATERIALS AND METHODS: Ethanolic extract (200 mg/kg/d) derived from M. alba fruit was employed in rabbits as a co-therapy (GM-al) with gentamicin (80 mg/kg/d) for a period of 3 weeks. Biochemical kidney functioning parameters, urinary isozymes, and histopathological examination were performed. RESULTS: The results showed that ethanol extract of Morus alba L. prevented alterations in serum creatinine (4.02 ± 0.14, p < 0.0001), blood urea nitrogen (54.18 ± 2.60, p < 0.0001), and serum uric acid levels (2.34 ± 0.12, p < 0.001). However, a decrease in creatinine clearance and urinary volume was observed in experimental groups. Histopathological examination and urinary enzymes excretion also suggested the protective role of the extract. DISCUSSION AND CONCLUSIONS: The co-administration of M. alba with gentamicin prevented renal functioning alterations expected with the use of gentamicin alone. Therefore, it can be concluded that M. alba to protect from kidney damage, which may be because of its free radical scavenging and diuretic properties.

A PROSPECTIVE PHARMACOLOGICAL REVIEW OF MEDICINAL HERBS, CUCUMIS MELO AND BERBERIS VULGARIS, COMMONLY USED IN THE TREATMENT OF RENAL DISEASES IN PAKISTAN.

The kidneys are important organs which have many functions in the body, including the production of hormones, absorbtion of minerals and the filtration of blood, producing urine. Their failure can be fatal, therefore, to focus the study of such herbs which may be useful in treating renal disease is the need of hour. In Pakistan, Cucumis melo and Berberis vulgaris has been commonly used for renal problems. In both of these plants were found flavonoids, alkaloids and terpenes, which may stand for their renal protective properties. Their reported vitamin E contents and antioxidant potentials also provide a base for their defensive mechanism, may be due to their free radical scavenging properties. Further, their diuretic and urinary tract anti-ulcer properties also support their traditional use in renal diseases. Their anti-histaminic and anti-cholinergic properties also provide symptomatic treatment by decreasing prostaglandin level and due to antispasmodic properties. Concluding, both of these plants can be used for renal problems, especially Cucumis melo, which have both the nutritive and medicinal properties. Therefore, the renal disease patients are advised to take much of this particular fruit, especially their seeds to make their kidneys healthy.

Evaluation of Prunus domestica gum as a novel tablet binder

To evaluate binding potential of Prunus domestica gum in tablets formulations. Six tablet batches (F-1B to F-6B) were prepared by wet granulation method, containing Avicel pH 101 as diluent, sodium diclofenac as model drug using 10, 15 and 20 mg of Prunus domestica gum as binder and PVP K30 was used as standard binder. Magnesium stearate was used as lubricant. Flow properties of granules like bulk density, tapped density, Carr index, Hausner’s ratio, angle of repose as well as physical parameters of the compressed tablets including hardness, friability, thickness and disintegration time were determined and found to be satisfactory. The FTIR spectroscopic analysis showed that the formulation containing plant gum is compatible with the drug and other excipients used in tablets formulation. Hence the plant gum has role as a potential binder in tablets formulations. The dissolution profile showed that tablets formulations containing Prunus domestica gum 15 mg/200 mg of total weight of tablet as binder showed better results as compared to PVP K30.

Para avaliar a propriedade aglutinante da goma Prunus domestica em formulações de comprimidos, seis lotes (F-1B para F-6B) foram preparados pelo método de granulação úmida, contendo Avicel pH 101 como diluente e diclofenaco de sódio como fármaco modelo, usando 10, 15 e 20 mg de goma de Prunus domestica como agente aglutinante e PVP K30 como aglutinante padrão. O estearato de magnésio foi utilizado como lubrificante. Propriedades de fluxo dos grânulos, como a densidade, índice de Carr, razão de Hausner, ângulo de repouso, bem como parâmetros físicos dos comprimidos, incluindo o tempo de dureza, friabilidade, espessura e desintegração foram determinados e se mostraram satisfatórios. A análise espectroscópica no FTIR mostrou que a formulação contendo goma vegetal é compatível com o fármaco e outros excipientes utilizados na formulação dos comprimidos. Assim, a goma vegetal tem papel potencial como aglutinante em formulações de comprimidos. O perfil de dissolução das formulações que contêm 15 mg/200 mg do peso total do comprimido em goma de Prunus domestica como aglutinante mostrou melhores resultados comparativamente ao PVP K30.

Simultaneous determination of timolol maleate, rosuvastatin calcium and diclofenac sodium in pharmaceuticals and physiological fluids using HPLC-UV.

A novel HPLC-UV method was developed for the simultaneous determination of timolol (TM), rosuvastatin (RST), and diclofenac sodium (DS) in pharmaceuticals, human plasma and aqueous humor using naproxen sodium as internal standard (IS). The target compounds were analyzed on Hypersil BDS C(18) column (250 mm × 4.6 mm, 5 µm), applying 0.2% triethylamine (TEA) and acetonitrile (ACN) (40:60, v/v), in isocratic mode as mobile phase, pH 2.75 adjusted with 85% phosphoric acid at a flow rate of 1 ml/min. The column oven temperature was kept at 45°C and the peak response was monitored at 284 nm after injecting a 50 µl sample into HPLC system. The direct liquid-liquid extraction procedure was applied to human plasma and bovine aqueous humor samples using mobile phase as an extraction solvent after deproteination with methanol. The different HPLC experimental parameters were optimized and the method was validated according to standard guidelines. The recoveries of the suggested method in human plasma were 98.72, 96.04, and 95.14%, for TM, RST, and DS, while in aqueous humor were 94.99, and 98.23%, for TM, and DS, respectively. The LOD values were found to be 0.800, 0.500, and 0.250 ng/ml, for TM, RST, and DS, respectively, while their respective LOQ values were 2.00, 1.50, and 1.00 ng/ml. The co-efficient of variation (CV) were in the range of 0.1492-1.1729% and 1.0516-4.0104%, for intra-day and inter-day studies, respectively. The method was found accurate in human plasma and bovine aqueous humor and will be applied for the quantification of these compounds in plasma, and aqueous humor samples using animal models and in pharmaceuticals.

Evaluation of chemical constituents and antinociceptive properties of Myricaria elegans Royle.

The phytochemical screening of Myricaria elegans Royle (Tamaricaceae) gave strongly positive results for terpenes. A total of six triterpenes were isolated from the CHCl3 fraction, including eleganene-A, eleganene-B, corsolic acid, betulin, ursolic acid, and erythrodiol. The in vivo antinociceptive investigation of the plant showed a significant increase in the tail-flick latency, accompanied by mild sedation and severe ataxia. Considering the known activities of some of the compounds isolated from the plant, it may be hypothesized that the increase in the tail-flick latency may be the combined effect of analgesia, ataxia, and sedation, rather than analgesia alone. These findings suggest M. elegans to be a potential source for activity-guided isolation of important natural compounds with a variety of effects.

Anti-inflammatory study on crude methanol extract and different fractions of Eremostachys laciniata.

CONTEXT: Eremostachys laciniata (L.) Bunge (Lamiaceae), which has been reported as a rich source of flavonoids, is one of the rarely explored species of the genus Eremostachys. OBJECTIVE: In this study, the crude methanol extract and different fractions of E. laciniata were investigated for in vivo anti-inflammatory properties. MATERIAL AND METHODS: Shade-dried leaves of E. laciniata were exhaustively extracted by percolation with methanol (80%) to obtain 250 g of crude methanol extract (El), followed by fractionation with different organic solvents to get the n-hexane (Elh), chloroform (Elc), ethyl acetate (Ele), butanol (Elb), and water (Elw) fractions. An in vivo anti-inflammatory study of the crude extract and sub-crude fractions was carried out in rats using the carrageenan model. RESULTS: The Ele fraction was found to be the most potent inhibitor of edema formation by inducing a maximum inhibitory effect of 74.2% at the 300 mg/kg dose, during 3 h post carrageenan injection. The El extract and Elc fraction also showed good anti-inflammatory properties at the same dose. DISCUSSION: The demonstration of excellent anti-inflammatory activity by the plant chiefly concentrating in the Ele fraction and the appearance of peak activity in the latter phase of the experiment suggested the presence of relatively low-polar substances with arachidonic acid metabolite inhibition property. CONCLUSION: The plant may be an excellent source in the future for activity-guided isolation of important anti-inflammatory substances.

Synthesis, characterization, antimicrobial and antitumor screening of some diorganotin(IV) complexes of 2-[(9H-Purin-6-ylimino)]-phenol.

A new series of diorganotin(IV) complexes of the type R(2)SnL(2) (R=Me, Et, Bu, Ph, Bz and L=2-[(9H-Purin-6-ylimino)]-phenol) have been synthesized, characterized by elemental analyses and their solid state configuration has been determined by various spectroscopic (IR, (1)H, (13)C, (119)Sn NMR, (119m)Sn Mössbauer) techniques. The results obtained on the basis of these techniques are in full concurrence with the proposed 2:1 stoichiometry. The title complexes have been screened against various microorganisms, fungi and human cell line KB, the results obtained showed that the bis(2-[(9H-Purin-6-ylimino)]-phenolate) diphenyltin(IV) complex exhibited excellent activity against all types of bacteria and fungi used, while bis(2-[(9H-Purin-6-ylimino)]-phenolate) diethyltin(IV) complex was found to have promising antitumor activity.

New antibacterial pentacyclic triterpenes from Myricaria elegans Royle. (tamariscineae).

Two new pentacyclic triterpenes eleganene-A (1) and eleganene-B (2), along with four known pentacyclic triterpenes betulin (3), ursolic acid (4), erythrodiol (5) and corosolic acid (6) were isolated from the aerial parts of Myricaria elegans. These compounds exhibited significant antibacterial activity. The structure of compounds 1 and 2 were deduced on the basis of their spectral analysis.